FibroBiologics Doses First Patients in DFU Trial, Posts $4.1M Q2 Loss
FBLG is trading near its 52-week low of $0.62 (13% above the low).
Summary
FibroBiologics initiated dosing in its Phase 1/2 trial of CYWC628 for diabetic foot ulcers, a key step for the clinical-stage biotech. Q2 financials show a $4.1M net loss with $1.7M in R&D and $2.4M in G&A expenses. The company ended June with $3.5M in cash, and the going concern warning and Nasdaq delisting notice from the recent 10-Q remain critical overhangs. Interim trial results are expected in the second half of 2026, with primary safety and efficacy data by year-end. This follows a series of dilutive financings, including a $9M private placement and a $3M public offering, as the company pushes toward multiple IND filings in Q4 2026.
At the time of this announcement, FBLG was trading at $0.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $0.62 to $13.16. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: PR Newswire.